Hims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024. In the quarter to June 2026, revenue grew 38.3%, EPS fell 294.7%, free cash flow grew 5.09% and total debt rose 40.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow HIMS
Hims & Hers Health, Inc. (HIMS) Altman Z-score
Hims & Hers Health, Inc.'s Altman Z-score for fiscal 2025 is 4.10, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 4.10 | (11.67) |
| FY2024 | 15.76 | 3.19 |
| FY2023 | 12.57 | (1.89) |
| FY2022 | 14.46 | 0.30 |
| FY2022 | 14.16 | 6.26 |
| FY2021 | 7.90 | (9.59) |
| FY2021 | 17.49 | 16.52 |
| FY2020 | 0.97 | (12.40) |
| FY2020 | 13.37 | 13.09 |
| FY2019 | 0.28 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.17 | — | 0.20 | |
| Retained earnings / total assets | (0.05) | — | −0.07 | |
| EBIT / total assets | 0.05 | — | 0.16 | |
| Market value of equity / total liabilities | 4.53 | — | 2.72 | |
| Sales / total assets | 1.09 | — | 1.09 | |
| Altman Z-score | Safe zone | 4.10 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Grey zone | 1.62 | ||
Z and Z″ put Hims & Hers Health, Inc. in different zones: safe zone by Z, grey zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 10.4× |
| ALKS Alkermes plc compare | 5.3× |
| RDY Dr. Reddy's Laboratories Ltd compare | 5.3× |
| LNTH Lantheus Holdings, Inc. compare | 4.3× |
| HIMS Hims & Hers Health, Inc. | 4.1× |
| INDV Indivior Pharmaceuticals Inc. compare | 3.3× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 1.9× |
| ELAN Elanco Animal Health Incorporated compare | 1.3× |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets